1%的Tapinarof奶油:儿科首次批准
1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. pdd@adis.com.
目前,Tapinarof 1% 乳液已批准用于患有亚托皮炎 (AD) 和斑块性牛皮的儿科患者. 这种阿里碳化合物受体 (AhR) 激动剂标志着局部皮肤病治疗的重要里程碑.
科学领域:
- 皮肤病学和免疫学,专注于皮肤平衡和免疫调节.
背景情况:
- 基碳化合物受体 (AhR) 在保持皮肤健康方面发挥着至关重要的作用.
- 塔皮纳洛夫 1% 奶油是一种局部的阿里碳化合物受体 (AhR) 激动剂,用于炎症性皮肤疾病.
研究的目的:
- 总结一下tapinarof奶油1%的发展里程碑.
- 为了突出最近对亚托皮性皮肤炎 (AD) 的儿科批准.
主要方法:
- 对tapinarof 1%奶油的临床发展和监管批准历史的审查.
主要成果:
- 塔皮纳罗夫奶油1%在2022年5月获得了美国初步批准,用于斑块性牛皮.
- 随后在日本 (2024年6月) 和美国 (2024年12月) 的批准扩大了其使用范围,包括为AD治疗的儿科患者.
结论:
- 塔皮纳 1% 奶油的开发已经取得了显著的进展,最终得到了它的第一个儿科适应症.
- 批准意味着对患有亚托邦性皮炎的儿科患者的局部治疗选择的进步.
更多相关视频
11:06Subretinal Implantation of RPE on a Carrier in Minipigs: Guidelines for Preoperative Preparations, Surgical Techniques, and Postoperative Care
Published on: November 11, 2022
08:40Surgical Technique of the 3-Dimensional-printed Personalized Hip Implant for the Treatment of Canine Hip Dysplasia
Published on: April 19, 2024
相关概念视频
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
FDA Approved Drugs: Changes to Approved Drugs
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Excretion
